Retatrutide vs MGF (Mechano Growth Factor)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →MGF (Mechano Growth Factor)
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | MGF (Mechano Growth Factor) |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Activates muscle satellite cells (stem cells) and promotes their proliferation without differentiation, priming them for fusion with existing muscle fibers during repair and growth. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Due to extremely short half-life (minutes), typical protocols use 100-200mcg injected directly into target muscles immediately post-workout. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Intramuscular injection into trained muscles within minutes of workout completion. Must be used immediately after reconstitution due to instability. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Injection site soreness, potential hypoglycemia, localized swelling. Short half-life limits systemic effects. |
| Best For |